Agilent Technologies Introduces Next-Generation Assay Kits for Its 2100 Bioanalyzer Lab-on-a-Chip Platform

18 New or Upgraded Assays Offer Improved Sensitivity, Sizing Range, Reproducibility, Sample Matrix Tolerance

PALO ALTO, Calif., Feb. 22, 2006

Agilent Technologies Inc. (NYSE: A) today introduced the Series II family of assay kits for the Agilent 2100 bioanalyzer platform. The Series II kits offer improvements in all specifications, including sensitivity, sizing range, robustness and sample matrix tolerance for RNA, DNA and protein.

Source: Agilent Technologies